ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

CONSUMER PROTECTION ALERT FOR SILVERSCRIPT PART D MEMBERS: A Class Action Lawsuit Has Been Filed Against CVS Health Corporation and Related Entities For Preventing SilverScript Members From Accessing Certain Generic Medications

The law firms of Kessler Topaz Meltzer & Check, LLP and Carella, Byrne, Cecchi, Brody & Agnello, P.C. inform current and former SilverScript Part D beneficiaries that the firms have filed a class action lawsuit against CVS Health Corporation, SilverScript Insurance Company, LLC, and other related entities, for violations of the Racketeer Influenced Corrupt Organizations (“RICO”) Act and other federal and state laws. The action, captioned Jones v. CVS Health Corporation, et al., Case No. Case 2:24-cv-01703, was filed in the United States District Court for the Eastern District of Pennsylvania.

The class action lawsuit alleges that SilverScript Part D beneficiaries have been prevented from accessing less costly, generic versions of the following brand name prescription drugs: Invega, Asacol HD, Renvela packets, Renvela tablets, Harvoni, Epclusa, Ventolin HFA, Canasa Rectal Suppository, and Advair Diskus Specifically, the lawsuit alleges that the Defendants, along with five of the largest manufacturers of brand name drug products, implemented a fraudulent scheme to prevent Medicare Part D beneficiaries covered by SilverScript plans from accessing cheaper generic versions of these drugs, which resulted in the beneficiaries only having access to the costlier brand name versions. As a result of their fraudulent scheme, the Defendants and their co-conspirators have profited at the expense of elderly patients suffering from the life-altering illnesses that these drugs treat.

Contact us today to find out your rights if you are a current or former SilverScript Part D beneficiary and have purchased one or more of the following drugs: Invega, Asacol HD, Renvela packets, Renvela tablets, Harvoni, Epclusa, Ventolin HFA, Canasa Rectal Suppository, and Advair Diskus.

You can contact attorney Jonathan Naji, Esq. of Kessler Topaz by calling (484) 270-1453 or by email at info@ktmc.com. You can also fill out our form by CLICKING HERE or go to: https://www.ktmc.com/cvs-and-silverscript-subscriber-class-action

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.

ABOUT CARELLA, BYRNE, CECCHI, BRODY & AGNELLO, P.C.

Carella, Byrne, Cecchi, Brody & Agnello, P.C. is one of the leading law firms in the New Jersey – New York metropolitan area, serving a diverse clientele ranging from small businesses to Fortune 500 corporations. Carella Byrne has led - or been part of the leadership team - in many of the nation’s most complex and important class actions affecting consumer rights. More about the law firm and its successes can be found at www.carellabyrne.com.

May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.